Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

News

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...

Home January 07, 2020
Home
News | Cardiac Diagnostics

December 19, 2019 — The U.S. Food and Drug Administration (FDA) has granted breakthrough status for a novel ECG-based ...

Home December 19, 2019
Home
News | Heart Failure

December 18, 2019 — BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today ...

Home December 18, 2019
Home
News | Heart Failure

December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System for delivering CCM therapy, announced the ...

Home December 12, 2019
Home
News | Heart Failure

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of ...

Home November 21, 2019
Home
Blog | Heart Failure

It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including ...

Home November 21, 2019
Home
News | Heart Failure

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of ...

Home November 21, 2019
Home
The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | Dave Fornell, Editor

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at the ...

Home November 19, 2019
Home
News | AHA

November 14, 2019 — More than a million Americans face a doubling in their risk of death during or while recovering from ...

Home November 14, 2019
Home
News

November 6, 2019 — Cleveland Clinic announced the Top 10 Medical Innovations for 2020 at a multimedia presentation last ...

Home November 06, 2019
Home
News | Magnetic Resonance Imaging (MRI)

October 21, 2019 — Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of ...

Home October 21, 2019
Home
The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | Dave Fornell, Editor

October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's ...

Home October 21, 2019
Home
News | Heart Failure

October 16, 2019 — Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay ...

Home October 16, 2019
Home
News | Heart Failure

October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve ...

Home October 04, 2019
Home
Subscribe Now